Carlsson, L M S
Romeo, S
Jacobson, P
Burza, M A
Maglio, C
Sjöholm, K
Svensson, P-A
Haraldsson, B
Peltonen, M
Sjöström, L
Article History
Received: 11 September 2013
Revised: 21 February 2014
Accepted: 1 April 2014
First Online: 6 May 2014
Competing interests
: Lena Carlsson reports receiving consulting fees from AstraZeneca and owning stock in Sahltech; Lars Sjöström reports serving as a member of the board of Lenimen, receiving lecture fees from AstraZeneca and Johnson & Johnson and providing an expert statement on drug effects and weight-loss effects on obesity for AstraZeneca. The remaining authors declare no conflict of interest.